Synovial sarcoma (SS), an aggressive soft tissue sarcoma, occurs at any age but often in young adults and has a predilection for the extremities ([@bib13]). This tumour accounts for 10% of all soft tissue sarcomas. According to the presence or absence of well-developed glandular epithelial cells, SS can be divided into two major histological types: monophasic and biphasic. More than a quarter of patients succumb to this tumour in the first 5 years after diagnosis, despite the best currently available management ([@bib18]; [@bib17]).

Cytogenetically, more than 95% of SS is characterised by the t(X; 18) (p11.2; q11.2) chromosomal translocation, which always represents the fusion of SS18 with either SSX1 or SSX2, or rarely with SSX4 ([@bib14]; [@bib4]; [@bib15]). The *SS18-SSX1* and *SS18-SSX2* fusion genes appear to be mutually exclusive in SS, and the fusion type is concordant in primary tumours and metastases and constant over the development of disease ([@bib23]). Detection of the *SS18-SSX* fusion gene with reverse-transcriptase polymerase chain reaction (RT-PCR) has been used as a sensitive diagnostic method for SS ([@bib31]; [@bib7]; [@bib15]). Although the function of this fusion gene is largely unknown, it is considered to have a critical role in oncogenesis and development of SS ([@bib4]; [@bib15]). Its inhibition by small interfering RNA can block the proliferation and migration of SS cells ([@bib24]; [@bib28]).

The clinical impact of this fusion gene has been described in many papers but remains debated. [@bib10] first reported that patients with the *SS18-SSX1* fusion gene had a significantly worse outcome than patients with *SS18-SSX2* fusion gene, and others found the same result ([@bib22]; [@bib9]; [@bib20]; [@bib23]; [@bib16]; [@bib27]). However, some findings indicated that the *SS18-SSX* fusion gene variants were not prognostically important in patients with SS ([@bib6]; [@bib29]). Moreover, the frequency of the two types might vary geographically in these patients ([@bib11]).

Here we wanted to clarify the distribution and prognostic value of the *SS18-SSX* fusion gene in Chinese patients with SS and investigated its involvement in cell proliferation and invasion.

Materials and methods
=====================

Patients
--------

After approval by Institutional Review Boards of Peking University People\'s Hospital (No. 0016781), consecutive SS cases at the Peking University People\'s Hospital from January 2000 and January 2012 were identified and reviewed retrospectively. Informed consent for the experimental use of surgical specimens was obtained from all patients in written form according to the hospital\'s ethical guidelines. Data included patient age at diagnosis, sex, tumour size, tumour site, surgery modality, histological type, histological grade using the Fédération Nationale des Centers de Lutte Contre le Cancer (FNCLCC) grading system ([@bib8]), and disease stage according to the International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) staging system ([@bib25]). Histological subtyping was performed on hematoxylin and eosin-stained sections, using the 2002 World Health Organization classification of tumours of soft tissue and bone ([@bib5]), and cases were divided into monophasic and biphasic categories. Amputation was included in wide excision. Tumour sites were divided into extremity (neoplasms of extremity only) and the trunk (including the pelvis, shoulder, inguinal region, and axillary region).

Cell culture and *SS18-SSX* fusion gene transfection
----------------------------------------------------

HEK 293T and NIH 3T3 cell lines obtained from the ATCC (American Type Culture Collection, Manassas, VA, USA) were grown in Dulbecco\'s modified Eagle\'s medium (DMEM, Gibco, NY, USA) supplemented with 10% fetal bovine serum (FBS, Gibco) and 10% bovine calf serum (BCS, Gibco), respectively. Cells were maintained at 37 °C in a humidified atmosphere with 5% CO~2~. Full-length human SS18-SSX1 (RefSeq: NM\_ 001007559.1) or SS18-SSX2 (RefSeq: NM\_ 005637.2) cDNA was inserted into the eukaryotic vector pCMV6-AC-GFP separately (purchased from OriGene Technologies, Inc., Cat. No: RG219498 and RG215192, respectively). 293T cells were transfected with the recombinant plasmids and vector alone (mock transfectants) using Lipofectamine 2000 reagent (Life Technologies, Carlsbad, CA, USA) as described by the manufacturer and cultured in DMEM supplemented with 10% FBS and 800 *μ*g ml^−1^ G418 (AMRESCO, OH, USA). 3T3 cells were transfected as described above but cultured in DMEM supplemented with 10% BCS and 250 *μ*g ml^−1^ G418.

RNA isolation and RT-PCR
------------------------

Total RNA was extracted from cells and frozen tumour fragments from all patients with SS using TRIzol reagent (Invitrogen, La Jolla, CA, USA) according to the manufacturer\'s protocol. Total RNA (2 *μ*g) was used for the reverse transcription with the cDNA Reverse Transcription kit (Invitrogen), following the manufacturer\'s instructions. The detection of SS18-SSX1 cDNA was performed by RT-PCR with the forward primer 5′-CAGGGCTACGGTCCTTCACA-3′and reverse primer 5′-GGTGCAGTTGTTTCCCATCG-3′. The identification of SS18-SSX2 cDNA was performed by RT-PCR with the forward primer 5′-GACCACCTCCACAACAGGGAT-3′ and reverse primer 5′-GGCACAGCTCTTTCCCATCA-3′. The amplification profile of the PCR consisted of 40 cycles of denaturation at 94 °C for 50 s, annealing at 58 °C for 30 s, and extension at 72 °C for 1 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control, with the forward primer 5′-TGGGCTACACTGAGCACCAG-3′ and reverse primer 5′-AAGTGGTCGTTGAGGGCAAT-3′ and was synthesised on the basis of the human GAPDH mRNA sequence (GenBank Accession No. BC013310). cDNA replaced with water is used as a negative control. The PCR products were analysed by electrophoresis on 1.5% agarose gels.

Cell proliferation assay
------------------------

Cell proliferation was determined using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. The cells were trypsinised, and 5 × 10^3^ cells per well were seeded into 96-well plates in triplicate. Cellular proliferation was determined once per day during the 5-day period. In brief, 20 *μ*l MTT (5 mg ml^−1^ in phosphate-buffered saline) was added to each well, and the cells were incubated at 37 °C in a humidified atmosphere containing 5% CO~2~. Cells were lysed after 4--6 h using cell lysis reagent (20% sodium dodecyl sulphate, 50% dimethylsulphoxide, pH 4.7), and absorbency was measured at 570 nm with an EL-311SX enzyme-linked immunosorbent assay reader (Bio-Tek Instruments, Winooski, VT, USA). This experiment was replicated three times.

*In vitro* migration and invasion assays
----------------------------------------

Migration and invasion assays were performed by seeding 3 × 10^5^ cells in 200 *μ*l DMEM on top of transwell cell culture inserts containing a polyethylene terephthalate membrane pre-coated with or without Matrigel (24-well inserts, 8.0-*μ*m pore size; Coster, Corning Inc., Corning, NY, USA). The lower chamber was filled with 0.8 ml DMEM with 10% FBS for 293T cells and 10% BCS for 3T3 cells. After incubation for 24 h, the non-migrating cells were scraped off, and the membranes were fixed and stained using the Diff-Quik stain kit (Sysmex Co., Hyogo, Japan). Cells that had migrated through the membranes were quantified by determination of the cell number in nine randomly chosen visual fields at × 200 magnification. This experiment was replicated three times.

Statistical analysis
--------------------

The results of proliferation, migration, and invasion assays were presented as the mean±s.e. The analysis of their differences was performed using *t*-tests and analysis of variance (ANOVA). The following variables were considered for the prognostic value: age at diagnosis, sex, tumour size, tumour site (extremity and trunk), surgery modality (wide and marginal excision), histological type, FNCLCC system, UICC system, and SS18-SSX fusion type. Associations of SS18-SSX fusion type and other prognostic values were analysed using the two-sided Pearson *χ*^2^-test. Survival curves were estimated by the Kaplan--Meier method and analysed by the log-rank test. Multivariate analyses on the basis of the stepwise Cox proportional hazards model were used to identify the most significant factors related to overall survival (OS). All statistical analyses were performed with the SPSS statistical software package 13.0 (SPSS, Inc., Chicago, IL, USA). All two-sided *P*-values \<0.05 were considered statistically significant.

Results
=======

Patients and tumour characteristics
-----------------------------------

In our series, 47 (51.1%) and 41 (44.6%) patients were detected to have the *SS18-SSX1* and *SS18-SSX2* fusion genes, respectively ([Figure 1](#fig1){ref-type="fig"}). Four patients (4.3%) were found not to have either of the fusion genes. Among the 88 patients with SS and the *SS18-SSX* fusion gene, 56 were men (63.6%) and 32 were women (36.4%). The mean age at diagnosis was 33 years, ranging from 11 to 58 years. A total of 54 tumours were located in an extremity (24 upper limbs and 30 lower limbs), 34 were truncal, including the shoulder (*n*=7), pelvis (*n*=16), spine (*n*=9), and axillary regions (*n*=2). Fifty-one tumours were smaller than 5 cm and thirty-seven were 5 cm or larger. The 88 tumours were histologically classified as either monophasic SS (*n*=50, 56.8%) or biphasic SS (*n*=38, 43.2%). For histological grade, 53 (60.2%) and 35 (39.8%) patients had grades 2 and 3, respectively. According to the UICC staging system, 50 (56.8%) and 38 patients (43.2%) were classified as having stage 1/2 and stage 3/4, respectively. Surgery modality for 88 patients included wide excision (*n*=57, including 16 amputations) and marginal excision (*n*=31). A total of 24 (27.3%) and 21 patients (23.9%) were given preoperative or postoperative radiotherapy and chemotherapy, respectively.

The mean follow-up time was 42.7 months, with a range from 12 to 110 months. Forty-nine patients (55.7%) died of their malignancy. Forty-four patients (50%) experienced a local recurrence, and twenty-eight (31.9%) had metastasis. Among patients with recurrence, eight had a second recurrence, and four had at least a third recurrence. The metastatic location included the lung (*n*=20), bone (*n*=3), pleura (*n*=4), brain (*n*=2), and lymph node (*n*=2). Three patients developed multiple metastases.

Association between SS18-SSX fusion type and other prognostic factors
---------------------------------------------------------------------

[Table 1](#tbl1){ref-type="table"} shows the associations between SS18-SSX fusion type and other factors. A significant association between histological type and SS18-SSX fusion type was observed (*P*=0.001). Tumours (*n*=47) expressing SS18-SSX1 fusion transcripts were monophasic (*n*=19) and biphasic (*n*=28); tumours (*n*=41) expressing SS18-SSX2 fusion transcripts were almost wholly monophasic (*n*=31) except for 10 biphasic SS cases.

Tumour size (\<5 cm or ⩾5 cm) was significantly associated with SS18-SSX fusion type (*P*=0.038). For SS with SS18-SSX2 fusion transcripts, there were 28 tumours (68.3%) smaller than 5 cm. SS18-SSX fusion type was not significantly associated with age at diagnosis, sex, tumour site (extremity and trunk), surgery modality (wide and marginal excision), FNCLCC grade, or UICC stage (all *P*\>0.05).

Survival analysis
-----------------

OS was significantly better among SS18-SSX2 cases (*P*=0.001), cases of tumours smaller than 5 cm (*P*\<0.001), cases involving patients younger than 33 years (*P*=0.018), FNCLCC grade 2 cases (*P*\<0.001), and UICC stage 1 or 2 (*P*\<0.001) ([Figure 2](#fig2){ref-type="fig"}). However, sex, tumour site, histological type, radiotherapy, chemotherapy, and surgery modality had no impact on OS ([Table 2](#tbl2){ref-type="table"}).

Cox regression identified that the SS18-SSX1 fusion type (RR=2.343; *P*=0.002), aggressive FNCLCC grade 3 (RR=2.478; *P*=0.006), and UICC stage 3 or 4 (RR=3.379; *P*=0.001) were the independently negatively predictive factors of OS ([Table 3](#tbl3){ref-type="table"}).

SS18-SSX1 but not SS18-SSX2 associated with cell proliferation, migration, and invasion
---------------------------------------------------------------------------------------

Having shown that SS18-SSX1 expression was associated with poorer OS than SS18-SSX2, we examined the molecular mechanism involved. 293T and 3T3 cells were transfected with plasmid DNA encoding the full-length SS18-SSX1 or SS18-SSX2. After G418 screening for several weeks, stable transfected cell lines expressing SS18-SSX1 and SS18-SSX2 were established. RT-PCR was used to identify the expression ([Figure 3](#fig3){ref-type="fig"}).

Next, we examined differences in the proliferation of *SS18-SSX1* and *SS18-SSX2* genes using MTT assays for stable transfectants. Cell proliferation was significantly promoted in cells transfected with the *SS18-SSX1* gene compared with cells transfected with the *SS18-SSX2* gene ([Figure 4](#fig4){ref-type="fig"}).

We evaluated the different effects of the *SS18-SSX1* and *SS18-SSX2* genes on migration and invasion using the Boyden chamber. Migration and invasion were significantly enhanced by SS18-SSX1 transfectants compared with SS18-SSX2 transfectants ([Figure 5](#fig5){ref-type="fig"}).

Discussion
==========

SS characterised by SS18-SSX fusion transcripts is an aggressive soft tissue sarcoma ([@bib8]; [@bib10]; [@bib17]). The aim of this present study was to identify the clinical impact of SS18-SSX fusion type in SS and the mechanism involved. Of the 92 patients analysed by PT-PCR, 88 were positive for a SS18-SSX fusion transcript, which is in accordance with the literature ([@bib14], [@bib15]; [@bib23]). Only four patients were not identified as positive for a fusion gene, and these cases were excluded from the analysis. The ratio of SS18-SSX1 and SS18-SSX2 has been about 2:1 in the majority of studies ([@bib7]; [@bib23]; [@bib16]; [@bib29]); however, [@bib27] reported that the ratio is close to 1:2 in Chinese patients with SS. In the present study, the ratio of SS18-SSX1 and SS18-SSX2 was close to 1:1, in agreement with another previous report ([@bib9]). Geographic differences in distribution of *SS18-SSX* genes may explain these discrepancies.

The associations of SS18-SSX fusion type and other clinicopathological parameters were analysed in the study. Many authors have observed that major biphasic SS contain the SS18-SSX1 fusion transcript and that monophasic SS mostly express the SS18-SSX2 fusion transcript ([@bib10]; [@bib16]; [@bib29]; [@bib27]). We also found that SS18-SSX2 fusion transcript was rarely observed in biphasic SS (*P*=0.001). Moreover, this series also revealed a statistically significant association between the fusion type and tumour size (*P*=0.038). [@bib6] have found that SS18-SSX1-positive tumours tended to be smaller (\<7 cm) than SS18-SSX2-positive tumours, but when they divided tumour sizes at a 5 cm cutoff, there was no significant difference. However, our results demonstrated that SS18-SSX2-positive tumours tended to be smaller than 5 cm (*P*=0.038). This association between the fusion type and tumour size has not been noted previously, and the MTT results further revealed that the SS18-SSX1-positive cells displayed more proliferative potential than SS18-SSX2-positive cells. [@bib29] reported that tumours with the SS18-SSX1 fusion transcript were always located in the extremities, whereas tumours with the SS18-SSX2 fusion transcript were equally distributed between extremities and the trunk. The association of SS18-SSX fusion type and tumour location in the present series was the reverse but not statistically significantly different.

The prognostic implication of SS18-SSX fusion type in SS has been reported in many papers, but the results are mixed. We found that patients with SS18-SSX1-positive tumours had substantially shorter OS than those with SS18-SSX2-positive tumours. In addition, SS18-SSX1-positive tumours showed a significant association with worse clinical outcome in univariate analysis and retained a significant factor for OS after adjustment for other prognostic factors in multivariate analysis, in accordance with a previous report in a Chinese population ([@bib27]). Tumour invasion of the bone, nerve, or vascular structures is an independent adverse prognostic factor for SS ([@bib6]). Our results also demonstrated that the cells with the SS18-SSX1 type behaved more invasively than those with the *SS18-SSX2* gene. The proliferation, migration, and invasion capacities of the SS18-SSX1-positive cells were much higher than in the SS18-SSX2-positive cells.

The prognostic value of histological type has been controversial. In earlier studies, patients with biphasic SS tumours had better outcomes ([@bib12]; [@bib3]). However, recent studies, including ours, identified no difference in OS between patients with monophasic and biphasic SS tumours ([@bib10]; [@bib17]; [@bib26]; [@bib20]; [@bib16]; [@bib6]; [@bib11]; [@bib27]). According to the FNCLCC grade, SS was divided into two groups: low grade (grade 2) and high grade (grade 3) ([@bib8]). The UICC stage was established according to histological grade, tumour size, lymph node metastasis, and distant metastasis, and we divided the cases into two groups on the basis of this system: stage 1/2 and stage 3/4. In this series, high histological grade and UICC stage were important and independent adverse predictors for OS, in keeping with other reports ([@bib6]; [@bib11]; [@bib27]).

Moreover, our results demonstrated that small tumour size (\<5 cm) was associated with a relatively favourable outcome but was not an independent predictor for OS. Larger tumour size has been identified as a negative clinical predictor and classified variously as 5 cm ([@bib26]; [@bib6]; [@bib27]), 7 cm ([@bib6]), and 8 cm ([@bib30]). We chose 5 cm as the cutoff point because it was used in the UICC/AJCC staging system ([@bib25]), and many reports have reported a tumour size of 5 cm or more to be a negative prognostic factor ([@bib10]; [@bib1]; [@bib19]; [@bib17]; [@bib26]).

Generally, younger patient age has been commonly noted as a significantly positive clinical prognostic factor. We chose the mean age at diagnosis (33 years) as the cutoff point and found a strong association between death from malignances and age greater than 33 years. This result is in keeping with some previous reports ([@bib1]; [@bib6]; [@bib27]); however, Spillane *et al* found that younger age was associated with a poor prognosis. Furthermore, a multi-institutional analysis yielded no correlation between age at diagnosis and prognosis of patients ([@bib16]).

The role of chemotherapy and radiotherapy in the treatment of SS is also controversial ([@bib21]; [@bib1]; [@bib30]; [@bib2]; [@bib29]). In our series, 24 (27.3%) and 21 patients (23.9%) were given preoperative or postoperative radiotherapy and chemotherapy, respectively, in a non-randomised manner. There was no evidence of an OS benefit for chemotherapy and radiotherapy in this group.

In conclusion, these results show that SS18-SSX1 and SS18-SSX2 can serve as potential independent prognostic factors for OS in patients with SS. In addition, SS18-SSX1-positive cells show more invasive tendencies than those that are SS18-SSX2 positive.
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![**The electrophoresis image of RT-PCR products of fusion gene.** The images of ten SS18-SSX1-and SS18-SSX2-positive patients were shown in the higher and lower panels separately. cDNA replaced with water is used as a negative control (NC).](bjc2013547f1){#fig1}

![The curves of overall survival according to (**A**) age at diagnosis, *P*=0.018; (**B**) fusion gene type, *P*=0.001; (**C**) International Union Against Cancer stage, *P*\<0.01; (**D**) tumour size, *P*\<0.01; (**E**) Fédération Nationale des Centers de Lutte Contre le Cancer grade, *P*\<0.01 in 88 patients with synovial sarcoma.](bjc2013547f2){#fig2}

![**The electrophoresis image of RT-PCR products of cells transfected with the recombinant plasmids.** 1 and 5 represent 293T cells transfected with SS18-SSX1 and SS18-SSX2 separately; 2 and 6 represent 3T3 cells transfected with SS18-SSX1 and SS18-SSX2 separately; 3 and 7 represent 293T cells transfected with vector to detect SS18-SSX1 and SS18-SSX2 separately; 4 and 8 represent 3T3 cells transfected with vector to detect SS18-SSX1 and SS18-SSX2 separately.cDNA replaced with water is used as a negative control (NC).](bjc2013547f3){#fig3}

![**Overexpression of SS18-SSX1 promoted cell proliferation than SS18-SSX2.** 3T3 and 293T cells were stably transfected with SS18-SSX1, vector, and SS18-SSX2 separately. Cell proliferation was assessed using MTT assays. 3T3 (**A**) and 293T (**B**) cells with SS18-SSX1 were more proliferative during 5-day period. The cells transfected with vector alone worked as a negative control (NC). This experiment was replicated three times.](bjc2013547f4){#fig4}

![**Cells with SS18-SSX1 showed more invasion and migration potential.** 3T3 and 293T cells were stably transfected with SS18-SSX1, vector, and SS18-SSX2. Cell invasion and migration assay was assessed by Transwell cell culture with or without Matrigel. Cells that had migrated through the membranes were quantified by determination of the cell number in nine randomly chosen visual fields at × 200 magnification. Average number of invasive or migratory cell number per field from three independent experiments+s.e. is at top. 3T3 (**A**) and 293T (**B**) cell invasion and migration were significantly enhanced by SS18-SSX1 gene (\**P*\<0.05, \*\**P*\<0.01). The cells transfected with vector alone is used as a negative control (NC). This experiment was replicated three times.](bjc2013547f5){#fig5}

###### Relationship between SS18-SSX fusion type and other factors

                          **Fusion gene**                 
  ----------------------- ----------------- ---- -------- -----------
  **Age**                                        2.331    **0.127**
  \<33                    21                25             
  ⩾33                     26                16             
  **Sex**                                        1.67     **0.196**
  Male                    27                29             
  Female                  20                12             
  **Size**                                       4.303    **0.038**
  \<5CM                   23                28             
  ⩾5CM                    24                13             
  **Histological type**                          11.049   **0.001**
  MSS                     19                31             
  BSS                     28                10             
  **Site**                                       2.842    **0.092**
  Extremity               25                29             
  Trunk                   22                12             
  **FNCLCC grade**                               1.014    **0.314**
  2                       26                27             
  3                       21                14             
  **UICC stage**                                 0.541    **0.462**
  1 or 2                  25                25             
  3 or 4                  22                16             
  **Surgery modalit**y                           0.39     **0.843**
  Wide excision           30                27             
  Marginal excision       17                14             

Abbreviations: BSS=biphasic synovial sarcoma; FNCLCC=Fédération Nationale des Centers de Lutte Contre le Cancer; MSS=monophasic synovial sarcoma; UICC=International Union Against Cancer.

###### Univariate analysis for 5-year overall survival with patient and tumour characteristics

  **Factor**              **No. of patients**   **5-year overall survival (%)**   ***P*-value (log-rank tests)**
  ----------------------- --------------------- --------------------------------- --------------------------------
  **Age**                                                                         **0.018**
  \<33                    46                    63                                 
  ⩾33                     42                    31.4                               
  **Sex**                                                                         **0.408**
  Male                    56                    51.7                               
  Female                  32                    46.1                               
  **Size**                                                                        **\<0.01**
  \<5CM                   51                    72.1                               
  ⩾5CM                    37                    15.9                               
  **Histological type**                                                           **0.193**
  MSS                     50                    41.4                               
  BSS                     38                    57.8                               
  **Site**                                                                        **0.05**
  Extremity               54                    58.2                               
  Trunk                   34                    36.1                               
  **FNCLCC grade**                                                                **\<0.01**
  2                       53                    70.6                               
  3                       35                    22.9                               
  **UICC stage**                                                                  **\<0.01**
  1 or 2                  50                    68.9                               
  3 or 4                  38                    22.7                               
  **Fusion gene**                                                                 **0.01**
  SS18-SSX1               47                    35.1                               
  SS18-SSX2               41                    63.3                               
  **Surgery modality**                                                            **0.5**
  Wide excision           57                    53.3                               
  Radical excision        31                    41.5                               
  **Radiotherapy**                                                                **0.056**
  No                      64                    21.5                               
  Yes                     24                    37.5                               
  **Chemotherapy**                                                                **0.143**
  No                      67                    44.4                               
  Yes                     21                    49.8                               

Abbreviations: BSS=biphasic synovial sarcoma; FNCLCC=Fédération Nationale des Centers de Lutte Contre le Cancer; MSS=monophasic synovial sarcoma; UICC=International Union Against Cancer.

###### Multivariate analysis for 5-year overall survival with patient and tumour characteristics

                        **Overall survival**   ***P*-value**   
  --------------------- ---------------------- --------------- -------
  SS18-SSX1/SS18-SSX2   2.343                  2.177--2.667    0.002
  FNCLCC grade 2/3      2.478                  1.291--4.775    0.006
  UICC stage1,2/3,4     3.379                  1.651--6.917    0.001

Abbreviations: FNCLCC=Fédération Nationale des Centers de Lutte Contre le Cancer; UICC=International Union Against Cancer.
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